Q/C Technologies is a small, early-stage company pivoting from pharmaceutical drug development into laser-based computing for blockchain and cryptocurrency infrastructure. The core product is the qc-LPU100, a laser processing unit (LPU) developed under an exclusive global license from LightSolver, an Israeli technology company. LPUs use photonic (light-based) processing to solve computationally intensive optimization problems that are expensive to run on traditional chips. Q/C Technologies is targeting three main use cases: blockchain and cryptocurrency infrastructure, Decentralized Physical Infrastructure Networks (DePin), and AI and high-performance computing workloads. The company acquired LPU Holdings in September 2025, bringing the LightSolver licensing arrangement in-house. As of the end of FY25, the qc-LPU100 remains in prototype and early-stage benchmarking, with no meaningful revenue generated. The intended revenue model includes hardware sales or leasing, subscription or usage-based access to LPU capacity, and licensing or royalty arrangements tied to blockchain platform integrations. The legacy pharmaceutical business holds two clinical-stage drug candidates — Isomyosamine and Supera-CBD — which Q/C Technologies is evaluating selling or licensing to fund the computing pivot. The company has only two full-time employees and is entirely dependent on external financing to complete prototype development, conduct pilot testing, and pursue initial commercial deployments.